Alívio do IRS é maior para 17% das famílias

[LUISSM3]

Boas Attentive,

Como é que no dia 27 de Agosto conseguiste colocar um gráfico com a data e valores do dia de hoje


Quero uma plataforma dessas...

Já viste o volume de hoje? (pois já tinhas visto em agosto )

[Soma e segue]

Oi luissm

Atingida a MM200 e se nada de estranho ocorrer, o ativo tem agora a possibilidade de retomar a tendência primária, após esta breve correção.

Os osciladores estão alinhados no TFH desde o dia 17/8 e no TFW o PKS já deu sinal, estando o RSI e o MACD um pouco atrasados mas com a 1ª e 2ª derivada do MACDH positivas.

Não resisti, hoje, adquiri algumas AKRX. Vamos ver se me safo nesta.

Partilho a minha AF e gráfico que é daqueles que gosto.

BNegócios

[LUISSM3]

Actualizando gráfico e confirmando as previsões.

Atingida a MM200 e se nada de estranho ocorrer, o ativo tem agora a possibilidade de retomar a tendência primária, após esta breve correção.

Os osciladores estão alinhados no TFH desde o dia 17/8 e no TFW o PKS já deu sinal, estando o RSI e o MACD um pouco atrasados mas com a 1ª e 2ª derivada do MACDH positivas.

Apenas o volume podia ser um pouco mais significativo.

[Blue Epsilon]

Reparei que este tópico foi criado pelo Luka.

Alguém sabe o que se passa com ele? Desapareceu por completo...

[LUISSM3]

Rompeu o canal e pode vir à MM200.

[LUISSM3]

Boas AC,

Tens novidades desta cotada?

Se se mantiver no canal, poderá vir ao limite inf e manter-se dentro.

[AC Investor Blog]

Continua na minha lista de favoritas e já mencionada várias vezes no blog. Novo máximo atingido na passada sexta-feira.

[Luka!]

Aggressive Growth Stock: Akorn, Incby Zacks

We last checked in on Akorn, Inc. (NASDAQ:AKRX) in August and things were looking good. So, how did shares weather the market turmoil that was just ahead?

Company Description

Akorn, Inc. makes multisource and branded pharmaceuticals. The company specializes in diagnostics and therapeutic products, hospital drugs and injectable pharmaceuticals.

Another Surprise

On Nov 1 Akorn reported another great quarter. Earnings per share came in at $0.08, 3 cents better than expected. Revenues surged 70% to $36.7 million, thanks largely to a recent acquisition but there was organic growth as well.

In the same release, Akorn raised its full year guidance as well. The company now expected revenue of between $130 million and $132 million. At that time the consensus was $123 million.

So, what did analysts think?

Estimates Keep Improving

As you might expect, analysts quickly raised earnings estimates. The Zacks Consensus Estimate for this year is up 4 cents, to $0.29. Back in 2010 the company’s profit was just a penny per share.

Next year’s average forecast is up 7 cents, to $0.38, for an expected growth rate of 32%.

Valuations

Shares of AKRX are going for more than 30 times this year’s estimates, but the potential growth gives them a PEG of 1.1. That is a decent value for a 28% 3-5 year growth rate.

The Chart

There has been some profit taking on the earnings news and recent market jitters, but the overall trend is still bullish.


http://www.dailymarkets.com/stock/2011/ ... orn-inc-2/

[Luka!]

Akorn, Inc. (AKRX) engages in the manufacture and marketing of diagnostic and therapeutic pharmaceutical products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. Market cap of $738.19M. TTM operating cash flow/common equity at 0.20 vs. 5-year average at -0.06.

Net institutional shares purchased over the current quarter at 7.7M, which is 11.40% of the company's 67.56M share float.
The stock is a short squeeze candidate, with a short float at 8.91% (equivalent to 5.91 days of average volume).

TECHNICAL ANALYSYS
Ascending tunnel
just above the lower line of the channel
RSI with room to higher fligths
>> BUY POINT